Overview

Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment

Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
To observe the efficacy of cefuroxime-containing bismuth quadruple regimen in the eradication treatment of Helicobacter pylori, and to evaluate whether it can be used as a remedial treatment for Helicobacter pylori after initial or repeated treatment failure.
Phase:
N/A
Details
Lead Sponsor:
Shanghai East Hospital
Treatments:
Bismuth
Cefuroxime
Cefuroxime axetil